antibodi
respons
studi
infecti
diseas
particularli
toxin
isol
pathogen
bacteria
inde
antibodi
qualiti
requir
protect
diphtheria
toxin
among
first
elucid
von
behr
kitasao
ehrlich
jern
howev
inabl
purifi
toxin
complex
biolog
materi
forc
immunologist
use
chemic
pure
substanc
order
quantit
studi
antigen
reaction
antibodi
evan
therefor
immunochemist
use
hapten
usual
small
phenyl
group
easili
synthes
variou
configur
could
link
larg
protein
heidelberg
eisen
siskind
small
size
could
pass
thenavail
dialysi
bag
measur
physicochem
paramet
antibodyantigen
interact
defin
bind
affin
specif
recent
becom
possibl
express
purifi
biolog
substanc
suffici
repeat
analys
vitro
also
correl
measur
protect
diseas
vivo
fazeka
de
st
groth
webster
staudt
gerhard
webster
rott
laver
et
al
bachmann
et
al
individu
defect
antibodi
respons
patient
bruton
diseas
antibodi
defect
suscept
infect
wilfert
et
al
graham
et
al
englund
et
al
mice
devoid
b
cell
mous
good
zak
kitamura
et
al
et
al
protect
neutral
antibodi
respons
particularli
acut
cytopath
agent
among
critic
defens
mechan
sabin
steinhoff
et
al
zinkernagel
et
al
respons
repres
result
long
coevolut
host
variou
infecti
agent
howev
shorter
gener
time
greater
number
adapt
infecti
agent
consider
faster
host
review
attempt
summar
evolutionari
point
view
evid
neutral
antibodi
nab
key
protect
speci
mani
virus
particularli
cytopath
one
virus
potenti
upset
balanc
host
pathogen
therefor
equilibrium
must
evolv
enabl
surviv
balanc
maintain
abil
host
mount
rapid
neutral
antibodi
respons
achiev
directli
encod
virusspecif
neutral
antibodi
germlin
thu
mandatori
assess
protect
capac
antibodi
vivo
adopt
transfer
experi
vitro
neutral
assay
rather
measur
antigen
bind
enzymelink
immunosorb
assay
elisa
interestingli
although
surprisingli
certain
geographi
antibodi
respons
local
iga
mucosa
system
shortliv
igm
longliv
igg
blood
addit
antibodi
neutral
virus
therebi
prevent
infect
also
trap
viru
spleen
prevent
reach
blood
therebi
enhanc
immun
respons
gener
b
cell
respons
particular
review
also
present
evid
gener
b
cell
neg
select
larg
regul
antigen
structur
avail
cognat
help
also
review
evid
support
notion
b
cell
memori
form
high
neutral
antibodi
serum
level
main
contributor
immunolog
memori
final
gener
specif
exampl
neutral
antibodi
respons
use
illustr
rule
govern
b
cell
respons
rule
also
discuss
respect
role
autoimmun
exploit
vaccin
develop
bone
marrow
b
cell
precursor
undergo
sequenti
recombinationactiv
gene
rag
mediat
rearrang
j
v
dj
element
immunoglobulin
ig
heavychain
variabl
region
v
h
v
j
element
ig
lightchain
variabl
region
v
l
tonegawa
express
function
ig
heavi
light
chain
promot
transit
precursor
b
cell
small
igmigdposit
matur
b
cell
autoreact
antibodi
specif
gener
random
rearrang
either
delet
nemaze
buerki
nemaze
buerki
nemaze
et
al
hartley
et
al
edit
secondari
v
l
possibl
v
h
replac
gay
et
al
radic
et
al
tieg
et
al
chen
et
al
chen
et
al
lang
et
al
pelanda
et
al
fang
et
al
nemaze
b
cell
emigr
bone
marrow
popul
secondari
lymphoid
organ
constitut
primari
b
cell
repertoir
restrict
number
v
j
gene
segment
encod
genom
limit
size
potenti
repertoir
howev
divers
preimmun
repertoir
mice
human
expand
hypermut
wherea
speci
rabbit
sheep
pig
cattl
use
gene
convers
diaz
flajnik
recent
suggest
togeth
hypermut
secondari
ig
gene
rearrang
may
also
contribut
repertoir
diversif
han
et
al
papavasili
et
al
pelanda
et
al
hertz
et
al
meffr
et
al
lopezmacia
et
al
wilson
et
al
howev
whether
consider
slower
process
confer
surviv
advantag
host
remain
formal
demonstr
primari
repertoir
vesicular
stomat
viru
vsv
specif
antibodi
analyz
isol
hybridoma
day
infect
kalink
et
al
surprisingli
clone
analyz
use
v
gene
belong
v
h
v
famili
despit
polyclon
origin
major
clone
express
ident
v
h
v
l
germlin
segment
antibodi
fail
bind
neutral
vsv
variant
select
presenc
one
particular
v
h
antibodi
appear
bind
subsit
within
major
antigen
site
glycoprotein
vsv
vsvg
analysi
primari
respons
influenza
viru
also
reveal
restrict
v
usag
predomin
segment
belong
v
gene
famili
clark
et
al
contrast
heavychain
variabl
region
gene
display
much
greater
divers
sever
v
h
famili
use
contrast
primari
respons
antibodi
hybridoma
isol
secondari
hyperimmun
antivsv
respons
express
divers
set
v
gene
belong
v
h
v
h
v
h
famili
kalink
et
al
major
antibodi
shown
bind
differ
subsit
major
antigen
site
vsvg
primari
respons
antibodi
thu
fine
specif
diversif
secondari
hyperimmun
respons
achiev
newli
appear
v
gene
combin
similar
find
obtain
analysi
secondari
respons
influenza
viru
v
region
usag
differ
consider
primari
respons
clark
et
al
virusneutr
antibodi
interestingli
antivsv
mab
isol
day
post
infect
irrespect
genet
element
express
devoid
somat
hypermut
kalink
et
al
indic
presenc
vsv
specif
mous
germlin
antibodi
repertoir
confirm
isol
vsvneutral
antibodi
fragment
phage
display
librari
gener
naiv
mice
lamarr
unpublish
result
find
remark
vsv
newworld
viru
rumin
mu
musculu
oldworld
rodent
therefor
presenc
vsvspecif
highaffin
antibodi
germlin
result
recent
coevolut
instead
suggest
gener
cytopath
virus
select
fit
avail
antibodi
repertoir
rather
vice
versa
roost
et
al
bachmann
et
al
similarli
antiinfluenza
primari
respons
antibodi
larg
devoid
somat
mutat
clark
et
al
contrast
primari
antibodi
secondari
hyperimmun
mab
display
hypermut
clark
et
al
kalink
et
al
nevertheless
primari
v
h
antibodi
hypermut
antivsv
antibodi
abl
neutral
viru
variant
howev
compar
germlin
antibodi
hypermut
antibodi
approxim
increas
abil
neutral
wildtyp
vsv
kalink
et
al
therefor
hypermut
alter
antibodi
specif
far
judg
bind
competit
assay
improv
bind
qualiti
neutral
capac
verifi
conclus
anoth
heterogen
group
vsvneutral
antibodi
typic
secondari
hyperimmun
respons
analyz
kalink
et
al
although
antibodi
express
numer
differ
light
chain
use
v
h
germlin
segment
belong
v
h
famili
combin
j
h
segment
hyperimmun
antibodi
contain
hypermut
despit
hypermut
antibodi
clonal
relat
show
singl
somat
amino
acid
substitut
viru
variant
resist
neutral
v
h
h
antibodi
could
gener
appar
bound
differ
subsit
within
major
antigen
site
vsvg
analyz
impact
common
amino
acid
substitut
viru
bind
neutral
secondari
respons
antibodi
v
h
h
group
express
monoval
recombin
singlechain
antibodi
consist
v
v
h
region
link
c
domain
kalink
et
al
antibodi
fragment
express
four
somat
amino
acid
exchang
v
h
wherea
v
l
germlin
antibodi
fragment
mutat
back
germlin
configur
mutat
introduc
v
h
encod
one
common
amino
acid
substitut
bind
hypermut
antibodi
fragment
better
germlin
antibodi
fragment
express
amino
acid
substitut
alon
improv
bind
wherea
substitut
affect
bind
antibodi
fragment
dimer
use
antic
antibodi
dimer
antibodi
fragment
improv
bind
wherea
bind
dimer
germlin
antibodi
fragment
improv
thu
avid
effect
contribut
bind
hypermut
antibodi
wherea
seem
major
impact
bind
germlin
antibodi
fragment
analysi
second
group
antibodi
confirm
previou
observ
hypermut
prerequisit
viru
neutral
howev
hypermut
improv
bind
neutral
vsv
vitro
level
avid
effect
seem
contribut
qualiti
antibodi
bind
lethal
viral
diseas
antivir
antibodi
gener
replac
target
v
h
region
endogen
v
h
element
locat
upstream
transgen
process
term
receptor
edit
gay
et
al
radic
et
al
tieg
et
al
chen
et
al
chen
et
al
lang
et
al
pelanda
et
al
fang
et
al
nemaze
experi
illustr
potenti
secondari
rearrang
diversif
limit
antibodi
repertoir
suggest
mechan
might
also
play
role
expand
normal
b
cell
repertoir
recent
studi
show
mice
lack
light
chain
costimulatori
molecul
signal
molecul
btk
suscept
control
mice
vsv
lcmv
infect
demonstr
plastic
b
cell
repertoir
fehr
et
al
affin
avid
concentr
paramet
protect
molecular
mechan
vivo
viru
neutral
remain
larg
undefin
howev
sever
studi
attempt
address
quantit
well
qualit
requir
neutral
mab
vivo
protect
passiv
transfer
experi
determin
vivo
protect
capac
vsv
nab
scid
sever
combin
immuno
defici
mice
devoid
b
cell
passiv
immun
variou
mab
challeng
vsv
day
later
brain
surviv
mice
assess
presenc
viru
secondari
hyperimmun
antibodi
bear
hypermut
protect
concentr
bachmann
et
al
kalink
et
al
one
primari
respons
antibodi
devoid
hypermut
protect
similar
concentr
wherea
other
protect
concentr
kalink
et
al
thu
primari
respons
rolf
zinkernagel
et
al
monoclon
antibodi
alon
protect
lethal
vsv
infect
higher
concentr
secondari
hyperimmun
antibodi
polyclon
sera
compar
effici
earli
late
sinc
peak
ig
respons
theoret
total
ig
antigen
specif
bachmann
et
al
funk
et
al
protect
serum
level
rapidli
obtain
germlin
antibodi
later
time
point
lower
percentag
serum
ig
antigen
specif
increas
protect
capac
gener
hypermut
would
advantag
vsv
protect
data
accord
prophylact
antibodi
dose
numer
virus
includ
rabi
viru
ebola
viru
coronaviru
mous
influenza
viru
respect
dietzschold
et
al
lamarr
talbot
mozdzanowska
et
al
wilson
et
al
surprisingli
concentr
ebola
virusspecif
antibodi
protect
experiment
anim
even
treatment
start
one
day
post
viru
exposur
postexposur
protect
hamster
rabi
viru
also
report
use
human
gproteinspecif
mab
dietzschold
et
al
role
fcmediat
function
bival
protect
viru
infect
also
investig
sever
anim
model
protect
lethal
murin
coronaviru
infect
could
observ
f
ab
fab
antibodi
fragment
passiv
transfer
prior
viral
challeng
lamarr
talbot
howev
protect
capac
fab
fragment
greatli
reduc
compar
bival
molecul
despit
similar
vivo
halfliv
reduct
protect
capac
monoval
antibodi
fragment
compar
f
ab
fragment
correl
decreas
affin
constant
result
suggest
fc
fragment
bival
absolut
requir
vivo
protect
avid
might
influenc
protect
capac
similar
conclus
reach
recombin
singlechain
antibodi
fragment
use
protect
experi
although
extrem
short
vivo
halfliv
greatli
reduc
efficaci
kalink
et
al
lamarr
et
al
studi
use
variou
viral
infect
model
reveal
sever
mechan
antibodi
capabl
neutral
viru
unexpect
given
complex
virusantibodi
interact
alon
togeth
host
cell
opson
antibodi
seem
major
protect
mechan
bacteri
infect
prevent
attach
therefor
infect
cell
probabl
major
antibodymedi
effector
mechan
virus
howev
gener
statement
justic
mani
studi
numer
potenti
effector
mechan
nab
mechan
neutral
extens
review
previous
dellaporta
westaway
dimmock
dimmock
iorio
bachmann
zinkernagel
stewart
nemerow
burton
et
al
discuss
detail
nevertheless
would
like
emphas
littl
realli
know
mechan
variou
categori
neutral
antibodi
activ
describ
prevent
adsorpt
impair
function
viral
surfac
protein
necessari
product
infect
follow
viru
entri
levin
et
al
intracellular
neutral
via
phdepend
inhibit
viru
fusion
vesicl
phagosom
aggreg
viru
pseudoneutr
result
reduct
replic
viral
particl
without
necessarili
chang
infect
singl
particl
walli
melnick
interestingli
neutral
virus
requir
bind
antibodi
half
avail
surfac
determin
order
prevent
viru
attach
entri
cell
shown
requir
neutral
rhabdovirus
may
hold
true
mani
envelop
virus
express
one
major
neutral
determin
flamand
et
al
kalink
et
al
bachmann
zinkernagel
hp
roost
unpublish
virus
polioviru
dulbecco
et
al
mandel
emini
et
al
influenza
viru
lafferti
antibodi
molecul
appear
suffic
inhibit
infect
differ
clearli
show
distinct
mechan
may
employ
antibodi
neutral
whether
neutral
polioviru
requir
oneor
multihit
mechan
still
debat
dulbecco
et
al
dimmock
dimmock
believ
onehit
neutral
model
may
oversimplif
probabl
gener
rule
bacteri
phage
also
use
examin
antibodyviru
interact
howev
phage
usual
possibl
attach
site
contrari
anim
virus
result
may
readili
transfer
despit
effect
neutral
properti
antibodi
may
also
enhanc
infect
cell
bear
fc
receptor
porterfield
includ
macrophag
dendrit
cell
potenti
b
cell
cell
endotheli
cell
halstead
lewi
et
al
mascola
et
al
battegay
et
al
viru
nab
measur
vitro
assay
either
plaqu
format
cytopath
virus
focu
format
noncytopath
virus
inhibit
elisa
bind
assay
less
reliabl
measur
nab
except
purifi
intact
viral
particl
use
inde
antibodi
display
neutral
capac
bind
intact
viral
particl
particularli
one
envelop
protein
express
rhabdovirus
bachmann
et
al
addit
abil
neutral
viru
antibodi
also
shown
act
conjunct
complement
role
complement
activ
enhanc
prevent
infect
well
document
least
virus
cooper
nemerow
ochsenbein
et
al
fact
complement
consumpt
often
use
readout
presenc
antivir
antibodi
howev
necessarili
indic
role
complement
protect
correl
neutral
capac
inhibit
hemagglutin
correl
better
neutral
although
two
assay
measur
paramet
addit
sensit
assay
quit
distinct
bachmann
et
al
therefor
care
must
taken
interpret
correl
conclus
antibodydepend
neutral
mechan
probabl
larg
due
block
effect
mechan
may
appli
howev
whether
mechan
observ
sole
vitro
relev
live
host
remain
evalu
recent
studi
provid
insight
structur
aspect
antibodi
inhibit
viru
attach
cell
specif
case
influenza
polioviru
rhinoviru
adenoviru
footandmouth
diseas
viru
review
stewart
nemerow
case
influenza
viru
bind
surfac
fab
fragment
intact
ig
hemagglutinin
occupi
significantli
larger
area
area
cover
sialic
acid
moieti
hemagglutin
order
versu
stewart
nemerow
case
human
rhinovirus
compris
mani
serotyp
seem
major
receptor
cellular
entri
previous
thought
nab
bind
outer
rim
canyon
form
viru
surfac
thu
prevent
entri
receptor
howev
recent
structur
evid
challeng
concept
show
fab
fragment
actual
penetr
bind
site
smith
et
al
studi
footandmouth
diseas
viru
shown
antibodi
induc
conform
chang
viru
surfac
protein
therefor
prevent
exposur
fusogen
domain
normal
trigger
receptor
bind
similar
mechan
postul
polioviru
human
immunodefici
viru
hiv
virus
mechan
neutral
interfer
event
occur
attach
host
cell
postul
experiment
illustr
structur
analys
possibl
far
taken
togeth
structur
studi
reveal
nab
either
directli
block
receptor
bind
trigger
structur
chang
may
influenc
cellular
entri
whether
interact
occur
physiolog
condit
vivo
particularli
serumrich
environ
remain
shown
structur
mechan
neutral
virus
requir
complex
natur
antibodi
natur
spontan
antibodi
present
sera
nonimmun
human
mice
avramea
herzenberg
kantor
coutinho
et
al
natur
antibodi
mainli
igm
isotyp
igg
iga
also
observ
natur
antibodi
polyspecif
although
antibodi
react
singl
antigen
also
present
periton
cell
shown
main
sourc
polyreact
antibodi
although
cell
may
also
particip
product
natur
antibodi
repertoir
casali
notkin
herzenberg
kantor
natur
antibodi
encod
germlin
gene
without
somat
mutat
stimulu
secret
natur
antibodi
larg
unknown
shown
b
cell
synthes
natur
antibodi
also
present
newborn
nude
germfre
antigenfre
mice
similar
reactiv
pattern
analyz
quantit
immunoblot
assay
bo
meeuwsen
hauri
et
al
possibl
explan
appar
antigenindepend
stimul
natur
antibodysecret
b
cell
may
b
cell
normal
secret
low
level
ig
trigger
crossreact
selfantigen
propos
natur
antibodi
may
play
role
mediat
immunoregulatori
function
hypothet
idiotypicantiidiotyp
network
theori
jern
coutinho
autoimmun
diseas
system
lupu
erythematosu
sle
cohen
tlaskalovahogenova
et
al
howev
main
physiolog
function
seem
earli
resist
infect
natur
antibodi
togeth
compon
innat
immun
belong
first
line
defens
microbi
infect
boe
et
al
ochsenbein
et
al
baumgarth
et
al
role
natur
antibodi
also
shown
protect
viral
infect
multipl
mechan
first
highli
specif
serotypespecif
igm
antibodi
directli
neutral
vsv
gobet
et
al
ochsenbein
et
al
normal
occur
hematogen
spread
viru
although
indic
mice
natur
igm
antibodi
also
transport
mucos
surfac
protect
local
influenza
viru
infect
second
igm
pentam
potenti
bind
ten
antigen
determin
per
molecul
therefor
form
larg
antigenantibodi
complex
would
effici
retain
spleen
lutz
et
al
process
control
spread
cytopath
infecti
agent
blood
shown
vsv
prevent
infect
vital
target
organ
ochsenbein
et
al
addit
observ
antibodydefici
mice
show
increas
suscept
virus
polioviru
must
distribut
target
organ
via
blood
circul
provid
indirect
evid
role
lachmann
davi
third
igm
potent
activ
complement
fearon
locksley
carrol
trigger
complement
cascad
directli
lead
lysi
invad
bacteria
provid
protect
viral
infect
effici
protect
howev
may
limit
due
fact
na
titer
rather
low
dose
cytopath
infecti
agent
reach
system
circul
high
natur
antibodi
first
line
defens
overrun
specif
nab
elicit
quickli
effici
prevent
infect
vital
target
organ
complement
compon
involv
host
protect
viral
infect
either
directli
indirectli
interact
virusinfect
cell
cooper
enhanc
neutral
capac
antibodi
complement
compon
may
occur
coat
virion
probabl
lower
extent
compon
shown
earli
experi
avian
infecti
bronchiti
complet
disassembl
viru
describ
berri
almeida
contrast
vitro
experi
use
vsv
show
activ
cleavag
product
incorpor
viral
envelop
prevent
infect
target
cell
without
actual
destroy
viral
particl
beeb
cooper
enhanc
antibodymedi
neutral
complement
recent
confirm
vivo
panel
vsvspecif
monoclon
antibodi
ochsenbein
et
al
anoth
way
direct
interact
complement
viru
could
enhanc
neutral
effici
target
complementco
viral
particl
complement
receptor
cr
express
cell
effect
document
express
b
cell
follicular
dendrit
cell
fdc
wherebi
opson
antigen
complement
enhanc
antigen
target
lead
effici
antigen
present
germin
center
gc
format
tew
et
al
carrol
recent
direct
enhanc
bcell
receptor
bcr
signal
transduct
also
describ
phenomenon
call
dual
antigen
recognit
simultan
recognit
antigen
bcr
complementbound
antigen
van
noesel
et
al
fearon
carter
follow
bind
form
complex
induc
crosslink
bcr
coreceptor
may
therebi
lower
threshold
b
cell
activ
mechan
shown
import
immun
variou
model
antigen
exampl
hen
egg
lysozym
hel
coupl
immunogen
hel
alon
dempsey
et
al
similarli
natur
antibodi
complement
shown
import
induct
tdepend
b
cell
respons
complementdefici
ahearn
et
al
molina
et
al
fischer
et
al
solubl
igmdefici
mice
ehrenstein
et
al
boe
et
al
contrast
immun
complement
complement
receptor
mice
differ
replic
virus
result
gener
neutral
antibodi
compar
control
fehr
et
al
ochsenbein
et
al
discrep
suggest
lower
threshold
b
cell
activ
import
mainli
tdepend
antibodi
respons
limit
amount
nonrepl
antigen
howev
gener
tdepend
antibodi
respons
requir
least
day
oxeniu
et
al
therefor
earli
tindepend
ti
antibodi
respons
crucial
control
rapidli
spread
virus
margin
zone
macrophag
long
recogn
import
gener
ti
antibodi
respons
bacteri
antigen
amlot
et
al
buit
et
al
recent
analysi
tineutr
antivir
igm
respons
also
reveal
import
role
target
complementopson
viru
margin
zone
macrophag
express
ochsenbein
et
al
concentr
local
antigen
crucial
induct
earli
ti
antibodi
respons
taken
togeth
natur
antibodi
recogn
pathogen
circul
activ
complement
cascad
therebi
target
antigen
splenic
margin
zone
allow
crosslink
bcr
result
earli
ti
product
neutral
igm
antibodi
interact
complement
virusinfect
cell
studi
sever
virus
welsh
et
al
mill
et
al
beeb
cooper
cooper
nemerow
cooper
appear
particularli
relev
noncytopath
virus
measl
viru
epsteinbarrviru
ebv
virus
activ
human
complement
cascad
via
altern
pathway
lead
lysi
infect
cell
mcconnel
et
al
sisson
et
al
lytic
effect
increas
antivir
igg
antibodi
probabl
bind
therebi
increas
resist
inactiv
fri
et
al
reiter
fishelson
allow
gener
convertas
increas
lysi
target
cell
howev
activ
complement
cascad
gener
lytic
complex
counterbalanc
cell
repair
mechan
protect
integr
nucleat
cell
shed
vesicl
contain
piec
damag
membran
import
role
complement
system
antivir
protect
suggest
fact
sever
virus
evolv
strategi
evad
complementmedi
lysi
either
use
complement
receptor
complement
control
protein
viral
receptor
produc
complement
block
modul
molecul
frade
et
al
lachmann
davi
rolf
zinkernagel
et
al
exampl
hiv
shown
carri
complement
control
protein
envelop
saifuddin
et
al
complement
receptor
interact
pathogen
natur
antibodi
thu
provid
host
protect
fcr
immun
cell
interact
igg
trigger
effector
function
inflammatori
respons
fcr
belong
divers
multigen
ig
superfamili
either
activ
inhibit
cellular
respons
ravetch
daeron
like
tcell
receptor
tcr
bcr
activ
fcr
member
immunoreceptor
tyrosinebas
activ
motif
itam
famili
compos
ligandbind
chain
associ
common
chain
reth
kurosaki
ravetch
cambier
therefor
mice
target
disrupt
chain
fail
express
highaffin
ige
receptor
highaffin
igg
receptor
ri
lowaffin
activ
receptor
riii
miyajima
et
al
analysi
mice
reveal
major
role
igg
evok
anaphylact
respons
bound
riii
effector
cell
includ
mast
cell
neutrophil
macrophag
natur
killer
nk
cell
role
ige
receptor
clearanc
helminth
infect
role
igg
fcr
immun
microbi
pathogen
streptococcu
address
sever
studi
result
suggest
suscept
infect
pathogen
influenc
presenc
absenc
fcr
gene
differ
observ
knockout
mice
heterozyg
litterm
summar
ravetch
clyne
similarli
analysi
differ
fcr
mice
vsv
lcmv
infect
also
reveal
role
fcr
control
virus
neutral
antibodi
respons
virusspecif
cytotox
cell
respons
viral
clearanc
infect
host
similar
fcr
mice
heterozyg
litterm
pericin
unpublish
result
taken
togeth
although
fcr
may
play
role
anaphylact
reaction
antibodymedi
autoimmun
diseas
probabl
even
tumor
model
situat
far
evid
fcr
crucial
involv
protect
varieti
bacteri
fungal
protozoan
helminth
viral
pathogen
ravetch
clyne
neutral
antibodi
respons
vsv
polioviru
virus
induc
rapidli
igm
respons
measur
day
peak
day
larg
tcellindepend
earli
phase
nude
tcelldeplet
mice
mount
good
igm
respons
intact
wildtyp
virion
live
uv
formalininactiv
use
immun
thu
highli
organ
repetit
dens
pack
neutral
epitop
usual
v
textur
neutral
antivir
antibodi
respons
exhibit
tip
glycoprotein
viru
envelop
abl
trigger
strong
igm
respons
absenc
help
thelpindepend
type
moreov
epitop
often
one
access
nab
b
cell
receptor
bcr
first
demonstr
influenza
virus
shown
antibodi
squeez
hemagglutinin
epitop
intact
virion
lafferti
fazeka
de
st
groth
shown
vsvneutral
epitop
express
singleenvelop
glycoprotein
lefrancoi
lyle
lefrancoi
wagner
luo
et
al
roost
et
al
roost
et
al
contrast
low
dose
monomer
glycoprotein
hemagglutinin
carri
neutral
determin
induc
earli
effici
igm
respons
bachmann
et
al
cours
earli
antibodi
respons
depend
viral
dose
probabl
natur
antibodi
complement
factor
bind
complex
discuss
ochsenbein
et
al
neutral
epitop
express
infect
cell
exhibit
less
repetit
less
rigid
distribut
cell
surfac
multim
repres
third
form
neutral
viral
epitop
induc
yet
differ
tcelldepend
igm
respons
case
necessari
help
link
convent
manner
noncogn
bystand
help
suffici
help
igm
respons
bachmann
et
al
bachmann
zinkernagel
result
indic
rigid
paracrystallin
form
glycoprotein
tip
space
nm
crosslink
specif
bcr
effici
process
requir
least
determin
trigger
b
cell
differenti
activ
antibodi
product
dintzi
et
al
dintzi
et
al
bachmann
et
al
zinkernagel
fehr
et
al
fehr
et
al
although
effici
crosslink
bcr
enhanc
b
cell
activ
note
type
igm
respons
also
dose
depend
sinc
low
dose
complet
depend
freer
et
al
ochsenbein
et
al
howev
suffici
dose
igm
respons
independ
rapid
suggest
distinct
probabl
great
import
pathophysiolog
point
view
howev
distinct
may
relev
selfnonselfdiscrimin
autoimmun
find
support
recent
model
propos
bcr
form
cluster
receptor
cluster
may
essenti
b
cell
select
induct
reth
et
al
antigenmedi
crosslink
minim
number
bcr
necessari
suffici
induc
b
cell
prolifer
antibodi
product
indic
antigen
signal
absenc
socal
second
signal
anerg
delet
b
cell
postul
other
bretscher
cohn
mueller
et
al
schwartz
cohn
langman
langman
cohn
matzing
b
cell
seem
take
antigen
organ
marker
reactiv
bachmann
et
al
zinkernagel
ochsenbein
v
inde
accumul
evid
suggest
regular
rigidli
order
ident
antigen
determin
less
b
cell
depend
control
cell
multimer
paracrystallin
structur
hallmark
surfac
antigen
infecti
agent
therefor
must
alway
consid
nonself
obviou
consequ
understand
antibodymedi
autoimmun
also
offer
new
concept
selfnonselfdiscrimin
b
cell
need
emphas
dose
persist
antigen
import
antigen
structur
howev
rel
import
two
factor
defin
separ
experiment
ie
multimer
antigen
bigger
monomer
antigen
therefor
affect
dose
structur
dintzi
et
al
ochsenbein
zinkernagel
point
later
similar
structur
may
exist
selfantigen
usual
access
b
cell
healthi
individu
contrast
multimer
nonself
antigen
monomer
determin
hallmark
selfantigen
blood
lymphat
system
b
cell
respons
selfantigen
therefor
strictli
regul
cognat
help
absent
selfantigen
weigl
effici
crosslink
bcr
requir
order
rapidli
expand
b
cell
earli
phase
infect
provid
suffici
igm
titer
limit
system
viru
distribut
subsequ
virusspecif
helper
cell
induc
around
day
post
infect
encount
expand
b
cell
pool
may
effici
induc
switch
igg
roost
et
al
zinkernagel
baumgarth
igg
respons
longer
live
halflif
protect
igm
respons
halflif
igg
molecul
also
diffus
effici
solid
tissu
central
nervou
system
smaller
igm
molecul
nevertheless
igm
effici
prevent
hematogen
spread
viru
suggest
surviv
vsvinfect
mice
incap
switch
igg
oxeniu
et
al
rapid
amplif
rare
b
cell
benefici
detriment
consequ
host
one
hand
effici
neutral
protect
antibodi
respons
acut
cytopath
infect
gener
hand
autoantibodi
autoimmun
diseas
could
potenti
induc
frequenc
neutral
antibodyproduc
b
cell
order
one
per
spleen
cell
correspond
one
per
b
cell
bachmann
et
al
frequenc
consider
lower
frequenc
determin
haptenspecif
dinitrophenyl
dnp
trinitrophenyl
tnp
specif
b
cell
order
bo
meeuwsen
similarli
frequenc
complex
protein
antigen
lysozym
ovalbumin
bovin
serum
albumin
time
higher
neutral
epitop
fact
correl
mani
antigen
determin
recogn
b
cell
complex
globular
protein
compar
v
usual
uniqu
neutral
epitop
expos
intact
viral
surfac
roost
et
al
roost
et
al
bachmann
zinkernagel
goldbaum
et
al
thu
neutral
antivir
antibodi
respons
protect
effici
viral
infect
wherea
antibodi
respons
mani
intern
viral
antigen
peptid
surfac
glycoprotein
usual
protect
reason
simpli
due
structur
limit
size
expos
determin
access
antibodi
mani
case
neutral
epitop
sole
determin
regularli
access
b
cell
intact
viral
surfac
altern
peripher
avail
determin
eg
polioviru
antibodi
may
therefor
effici
prevent
dock
appropri
receptor
neutral
epitop
mani
virus
therefor
select
longtim
coevolut
repres
singl
antigen
site
critic
prevent
viru
infect
therefor
surpris
close
relat
virus
share
greater
protein
sequenc
intern
structur
nonstructur
antigen
vari
singl
neutral
antigen
site
form
neutral
epitop
differ
defin
call
serotyp
definit
serotyp
distinct
virus
induc
crossprotect
respect
nab
despit
fact
share
helper
cell
cytotox
cell
determin
gupta
et
al
roost
et
al
zinkernagel
also
overemphas
antibodi
intern
viral
antigen
gener
irrelev
import
antivir
protect
structur
neutral
determin
usual
defin
area
built
sever
protein
loop
rotavirus
influenza
arenavirus
three
loop
seem
involv
form
neutral
determin
situat
probabl
realiti
even
complex
relev
glycoprotein
compos
three
four
interact
unit
webster
et
al
jackson
et
al
burn
buchmeier
select
case
linear
epitop
shown
induc
nabsfor
exampl
footandmouth
diseas
viru
bittl
et
al
brown
xiao
et
al
loop
hiv
robinson
mitchel
poignard
et
al
gener
except
confirm
rule
neutral
site
form
complex
loop
structur
loop
hiv
may
particularli
reveal
exampl
antibodi
induc
loop
neutral
artifici
lab
strain
usual
confer
protect
infect
primari
isol
fact
neutral
epitop
hiv
glycoprotein
seem
extrem
conform
depend
compos
least
two
separ
region
protein
engag
sequenti
infect
cho
et
al
neutral
epitop
determin
xray
crystallographi
polioviru
influenza
adenovirus
rhinovirus
mani
virus
inform
still
miss
approxim
deduc
mutat
analysi
howev
indirect
relationship
v
amino
acid
exchang
structur
consequ
render
interpret
result
gener
difficult
laver
et
al
far
analyz
simpl
notion
nab
cover
uniqu
antigen
site
expos
viru
surfac
andor
bind
receptorbind
structur
may
still
oversimplif
remain
attract
perhap
rather
gener
explan
see
later
gener
rule
tb
cooper
induct
helper
cell
macrophag
antigenpres
cell
apc
virusspecif
b
cell
describ
model
situat
textbook
paul
nevertheless
interest
observ
made
analyz
tb
cell
interact
protect
neutral
antibodi
respons
involv
first
limit
frequenc
neutral
b
cell
helper
cell
second
rel
import
help
specif
viral
envelop
versu
intern
antigen
point
neutral
b
cell
low
frequenc
therefor
induct
rare
b
cell
must
effici
particularli
earli
phase
viral
infect
antigen
scarc
usual
strictli
local
surprisingli
b
cell
major
limit
factor
neutral
antibodi
respons
amount
activ
state
helper
cell
charan
zinkernagel
document
first
immun
mice
one
serotyp
vsv
vsvind
month
challeng
second
vsv
serotyp
vsvnj
two
vsv
serotyp
share
virtual
helper
cytotox
cell
epitop
therefor
first
infect
prime
specif
ctl
helper
cell
challeng
infect
reveal
howev
neutral
antibodi
respons
gener
strictli
primari
type
charan
zinkernagel
gupta
et
al
find
suggest
prime
b
cell
rather
helper
cell
may
import
induc
protect
immun
mediat
antibodi
contrast
convent
view
develop
model
studi
analyz
specif
b
cell
respons
classic
hapten
carrier
system
mitchison
katz
benacerraf
earli
studi
clearli
show
haptenspecif
b
cell
limit
wherea
amount
avail
prime
help
limit
antibodi
respons
qualit
quantit
howev
point
frequenc
haptenspecif
b
cell
usual
high
order
one
per
contrast
much
lower
frequenc
virusspecif
neutral
b
cell
one
per
summari
experi
provid
strong
evid
b
cell
limit
factor
neutral
antibodi
respons
mani
acut
cytopath
virus
presum
also
bacteri
toxin
protein
bacteria
parasit
charan
zinkernagel
roost
et
al
bachmann
zinkernagel
zinkernagel
correl
well
v
yewdel
et
al
nathanson
martin
sabin
sabin
fazeka
de
st
groth
webster
rott
laver
et
al
liang
et
al
nathanson
mcfadden
ada
crucial
role
neutral
antibodi
antivir
protect
exclud
possibl
highli
activ
effector
cytotox
cell
helper
cell
could
also
particip
protect
zweerink
et
al
effro
et
al
howev
antigen
elimin
quickli
cell
effector
phase
usual
short
week
roost
et
al
importantli
easili
induc
maintain
vaccin
discuss
cell
specif
either
envelop
glycoprotein
intern
antigen
equal
effici
abil
help
neutral
b
cell
switch
igm
igg
liang
et
al
oxeniu
et
al
interestingli
howev
switch
b
cell
specif
intern
antigen
virtual
exclus
mediat
helper
cell
specif
particular
antigen
contrast
cell
specif
viral
antigen
support
switch
b
cell
specif
viral
surfac
protein
observ
strongli
support
view
intact
viru
particl
taken
neutral
antibodyproduc
b
cell
subsequ
present
viral
antigen
major
histocompat
complex
mhc
class
ii
wherea
switch
b
cell
specif
intern
viral
antigen
requir
antigen
releas
infect
cell
viral
particl
order
taken
histor
neg
select
b
cell
express
specif
selfantigen
postul
major
mechan
mainten
toler
ehrlich
horror
autotoxicu
ehrlich
burnet
propos
neg
select
immun
reactiv
time
distinct
b
cell
yet
known
focus
exclus
b
cell
burnet
fenner
notion
expand
nossal
cowork
includ
concept
anergi
nossal
recent
igmbcr
transgen
model
use
document
neg
select
basi
absenc
autoantibodi
respons
goodnow
et
al
nemaze
buerki
nemaze
buerki
nemaze
et
al
lysozymespecif
igm
transgen
mice
cross
mice
express
lysozym
show
number
specif
b
cell
reduc
compar
control
goodnow
et
al
similarli
k
igm
transgen
b
cell
larg
delet
transgen
mice
cross
k
mice
nemaze
buerki
sinc
antigen
express
solubl
product
v
serum
fail
delet
b
cell
compar
extent
conclus
transgen
igm
situat
membranebound
selfantigen
delet
selfspecif
b
cell
effici
wherea
solubl
antigen
serum
fail
nemaze
et
al
basten
et
al
conceptu
view
base
experi
conflict
number
clinic
experiment
observ
complet
support
neg
select
anergi
model
fact
autoantibodi
readili
detect
often
observ
infect
particularli
chronic
infect
solubl
self
antigen
also
membraneexpress
antigen
eg
acetylcholin
receptor
recognit
polyclon
stimul
lipopolysaccharid
could
stimul
b
cell
absenc
cognat
help
reveal
presenc
b
cell
readili
secret
autoantibodi
normal
individu
coutinho
moller
moller
one
inher
problem
observ
interpret
assay
measur
autoantibodi
autoreact
cell
necessarili
reflect
vivo
reactiv
nevertheless
clinic
relev
autoimmun
diseas
involv
one
autoantibodi
specif
teal
mackay
rose
mackay
strong
indic
autoantibodi
autoreact
b
cell
rare
except
data
obtain
antibodi
transgen
model
differ
observ
separ
studi
antibodi
respons
vsvneutral
epitop
express
mice
membraneassoci
solubl
antigen
mice
immun
intact
virion
live
uvirradi
formalinfix
promptli
induc
tcellindepend
igm
respons
bachmann
et
al
sinc
intact
virion
contain
intern
antigen
offer
help
neutral
antibodi
respons
effici
switch
igg
contrast
purifi
vsvg
deliv
adjuv
fail
induc
neutral
igm
igg
respons
result
indic
highaffin
b
cell
still
present
vsvg
transgen
mice
addit
suggest
b
cell
may
less
respons
monomer
oligomer
antigen
wherea
would
trigger
effici
highli
repetit
self
antigen
recent
find
confirm
antik
k
transgen
mice
respond
mimick
antigen
coupl
bacteri
virus
kouskoff
et
al
remain
evalu
whether
result
parallel
find
obtain
vsv
reflect
presenc
low
avid
antibodi
assess
elisa
anoth
exampl
demonstr
b
cell
gener
toler
anerg
even
high
level
solubl
antigen
seen
mice
infect
noncytopath
lcmv
mice
elimin
viru
acut
infect
becom
carrier
high
viral
titer
organ
pfuml
serum
carrier
mice
possess
antibodi
detect
elisa
specif
sever
viral
antigen
hotchin
sikora
oldston
v
oldston
et
al
moskophidi
et
al
interestingli
day
infect
celldefici
mice
high
titer
antivir
nab
gener
suffici
eventu
elimin
viru
even
complet
absenc
cytotox
cell
ciurea
et
al
thu
also
model
b
cell
toler
helper
cell
induc
earli
infect
suffici
provid
necessari
help
help
may
eventu
exhaust
viru
persist
high
level
one
could
still
argu
even
high
viru
titer
blood
solid
organ
suffici
toler
b
cell
howev
mice
infect
utero
carrier
mother
becom
toler
helper
cytotox
cell
level
unabl
gener
nab
row
hotchin
lehmanngrub
suggest
case
avail
help
limit
factor
rather
potenti
autoreact
b
cell
battegay
et
al
matloubian
et
al
oxeniu
et
al
b
seiler
et
al
accumul
evid
suggest
b
cell
neg
select
instead
either
fail
induc
low
dose
monomer
antigen
absenc
help
gener
shortliv
igm
respons
littl
patholog
consequ
host
ochsenbein
et
al
effici
antigen
crosslink
bcr
togeth
bind
complement
margin
zone
macrophag
key
trigger
effici
igm
respons
switch
longlast
igg
respons
presenc
classic
cognat
help
seiler
et
al
ochsenbein
et
al
via
parametersantigen
structur
antigen
dose
time
durat
avail
helpthat
longlast
antibodi
respons
regul
learn
antivir
antibodi
respons
understand
autoantibodi
respons
gener
true
antigen
structur
antigen
amount
avail
help
critic
factor
regul
usual
absenc
b
cell
autoantibodi
respons
young
host
induct
respons
reflect
breakdown
defect
one
regulatori
requir
basic
point
view
interest
note
autoantibodi
respons
autoimmun
diseas
often
compris
specif
highli
repetit
determin
collagen
dna
acetylcholin
receptor
etc
dintzi
et
al
dintzi
et
al
zinkernagel
et
al
bachmann
et
al
zinkernagel
schult
et
al
observ
support
idea
crosslink
polymer
determin
trigger
b
cell
effici
thu
amplifi
frequenc
like
could
switch
either
specif
bystand
help
worth
emphas
initi
mani
autoantibodi
respons
diseas
associ
infect
vaughn
et
al
rose
mackay
jansen
et
al
ludewig
et
al
ludewig
et
al
presum
infect
lead
releas
larg
amount
selfantigen
gener
v
inflammatori
signal
activ
antigenpres
cell
also
particularli
interest
note
mani
chronic
autoantibodi
immun
respons
associ
gener
new
secondari
lymphoid
structur
target
organ
autoantibodi
specif
haschimoto
thyroid
diseas
rheumatoid
arthriti
excel
demonstr
format
new
secondari
lymphoid
tissu
correl
chronic
persist
autoantibodi
respons
neoform
also
induc
repetit
inject
dendrit
cell
present
neoselfantigen
ludewig
et
al
chronic
infect
persist
peripheri
may
also
trigger
format
lymphoid
structur
enhanc
autoimmun
b
cell
respons
summari
induct
mainten
autoantibodi
respons
enhanc
repetit
autoantigen
structur
chronic
respons
lead
perpetu
inflammatori
event
format
new
lymphoid
tissu
within
target
organ
investig
potenti
repetit
antigen
structur
initi
autoantibodi
respons
viru
particl
use
matrix
display
antibodi
highli
repetit
fashion
gener
antiantibodi
similar
found
rheumatoid
arthriti
monitor
mice
immun
either
vsv
particl
monoclonalneutr
igm
antibodi
develop
antiantibodi
wherea
mice
immun
vsv
particl
complex
antivsv
antibodi
readili
mount
antiidiotypespecif
antibodi
respons
similarli
gramneg
bacteria
complex
monoclon
antibodi
use
immun
rheumatoid
factor
antibodi
constant
antibodi
region
induc
antibodi
bacterium
inject
alon
situat
inject
lipopolysaccharid
lp
togeth
complex
necessari
order
break
b
cell
unrespons
selfantigen
normal
present
high
concentr
serum
studi
illustr
potenti
high
concentr
repetit
antigen
structur
induc
autoantibodi
least
two
exampl
autoantibodi
induct
use
similar
approach
report
recombin
bovin
papillomavirus
construct
express
peptid
extracellular
loop
mous
chemokin
receptor
within
immunodomin
epitop
main
papillomaviru
envelop
protein
chackerian
et
al
inject
recombin
papillomaviru
induc
autoantibodi
block
regul
upon
activ
normal
cell
express
secret
rant
bind
cellular
entri
hiv
although
occur
without
appar
induct
autoimmun
diseas
howev
induct
clinic
autoimmun
describ
patient
hepat
c
viru
hcv
infect
perfect
analog
antiantibodi
studi
describ
serum
patient
suffer
chronic
hcv
infect
contain
immun
complex
hcvantihcv
antibodi
cryoglobulin
distinct
type
rheumatoid
factor
interestingli
electronmicroscop
analysi
reveal
complex
highli
repetit
paracrystallin
structur
v
et
al
deposit
complex
tissu
kidney
skin
lead
autoimmun
diseas
known
mix
cryoglobulinemia
go
special
reveal
exampl
neutral
antibodi
respons
virus
let
us
restat
gener
rule
fenner
sabin
mim
nathanson
mcfadden
zinkernagel
follow
viru
infect
mucosa
local
iga
immun
respons
probabl
import
still
poorli
understood
brandtzaeg
macpherson
et
al
viral
spread
peyer
patch
drain
lymph
node
induc
primari
immun
respons
b
helper
cell
result
local
system
iga
igm
igg
product
subsequ
local
infect
viru
usual
replic
drain
lymph
node
day
spread
system
johnson
mim
mim
lead
distribut
antigen
target
organ
includ
skin
central
nervou
system
kidney
lung
spleen
system
distribut
import
enabl
viru
spread
horizont
via
aerosol
stool
urin
spread
cytopath
virus
may
kill
host
control
earli
igm
immun
respons
initi
local
lymph
node
spleen
eventu
control
system
local
infect
sequenti
induct
immun
respons
key
import
control
gener
infect
fenner
although
entrap
viru
within
secondari
lymphoid
organ
may
also
import
particularli
rapidli
induc
respons
virus
reach
blood
directli
arthropodborn
virus
papillomavirus
exclus
infect
skin
mucos
cell
usual
basal
cell
epithelium
strictli
local
fashion
replic
product
termin
differenti
cell
eg
keratinocyt
tindl
frazer
frazer
et
al
effector
b
cell
even
langerhan
cell
easili
access
cell
skin
addit
differenti
cell
normal
releas
antigen
emigr
local
lymph
node
therefor
papillomaviru
antigen
initi
transport
lymph
node
infect
may
ignor
immun
system
long
period
time
kundig
et
al
ochsenbein
et
al
rabi
viru
use
compar
tactic
rather
skin
initi
resid
within
axon
retroaxon
flux
viru
access
b
cell
reach
secondari
lymphoid
organ
stage
infect
rabi
viru
yet
cytopath
therefor
viral
antigen
pick
macrophag
apc
thu
reach
drain
lymph
node
viru
reach
neuron
bodi
lyse
viru
spread
appear
rapid
immun
respons
usual
induc
late
benefit
v
host
postexposur
vaccin
inactiv
viru
seem
shorten
delay
may
deliv
viru
antigen
drain
lymph
node
induc
nab
may
favor
time
condit
limit
ongo
viru
transport
prevent
substanti
central
nervou
tissu
damag
baer
cleari
murphi
normal
antibodi
provid
protect
virus
case
may
actual
enhanc
infect
enhanc
viral
infect
mostli
studi
vitro
cell
suscept
viru
infect
bear
fc
andor
complement
receptor
antibodyco
viru
infect
cell
via
fcr
rather
via
specif
receptor
mani
nonor
lowcytopath
virus
suspect
use
antibodi
enhanc
infect
includ
hiv
takeda
et
al
robinson
et
al
homsi
et
al
dengu
virus
halstead
perhap
hcv
first
observ
made
flavivirus
hawk
et
al
hawk
larg
extend
halstead
cowork
halstead
describ
antibodydepend
enhanc
dengu
viru
replic
cultur
peripher
blood
leukocyt
human
primat
extent
serotyp
differ
contribut
viral
infect
via
fcr
whether
antibodydepend
enhanc
play
major
role
vivo
howev
still
clear
virus
dengu
howev
lowavid
antibodi
may
enhanc
earli
uptak
new
serotyp
therefor
render
second
infect
immun
patient
pathogen
first
infect
burk
et
al
moren
thein
et
al
classic
explan
sever
hemorrhag
diseas
repetit
dengu
viru
infect
similar
mechan
may
appli
persist
virus
escap
nab
may
also
explain
earli
death
kitten
inocul
infecti
felin
periton
viru
follow
passiv
transfer
antivir
antibodi
weiss
scott
addit
arenaviru
infect
includ
lcmv
shown
enhanc
vitro
like
also
vivo
lewi
et
al
ochsenbein
et
al
acquir
immunosuppress
virusspecif
lymphocyt
occur
cell
destroy
antigenpres
cell
dendrit
cell
macrophag
therebi
impair
induct
immun
respons
mim
wainwright
brojorgensen
volkert
silberman
et
al
biberfeld
et
al
racz
et
al
leist
et
al
odermatt
et
al
althag
et
al
tishon
et
al
borrow
et
al
seiler
et
al
mechan
might
help
explain
long
delay
appear
neutral
antibodi
follow
noncytopath
viru
infect
hiv
moor
et
al
pilgrim
et
al
carotenuto
et
al
hbv
alberti
v
planz
et
al
detail
analys
process
lcmv
infect
reveal
follow
interest
virushost
immun
relationship
earli
phase
infect
lcmv
seem
preferenti
infect
splenic
margin
zone
macrophag
mim
tosolini
jacob
cole
dendrit
cell
peripheri
secondari
lymphoid
organ
infect
cell
appear
subsequ
destroy
earli
induc
effector
cytotox
cell
althag
et
al
tishon
et
al
borrow
et
al
sevilla
et
al
treatment
antibodi
prevent
acut
immunopatholog
lymphohematopoiet
organ
battegay
et
al
binder
et
al
immunopatholog
destruct
antigenpres
cell
margin
zone
hamper
humor
tcellmedi
immun
respons
seiler
et
al
virusinduc
acquir
immunosuppress
seem
facilit
establish
longterm
persist
infect
noncytopath
viru
lcmv
shown
antibodi
respons
intern
viral
antigen
includ
nucleoprotein
membraneanchor
part
glycoprotein
drastic
impair
gener
immunosuppress
battegay
et
al
howev
neutral
antibodi
respons
greatli
reduc
even
prevent
complet
day
differ
correl
observ
hybridoma
specif
neutral
determin
frequent
infect
lcmv
wherea
specif
nucleoprotein
planz
et
al
find
suggest
intact
viru
particl
taken
neutral
antibodyspecif
b
cell
via
specif
bcr
viru
could
replic
within
cell
infect
b
cell
therefor
express
viral
peptid
associ
mhc
class
antigen
becom
suscept
destruct
cytotox
lymphocyt
ctl
contrast
nucleoproteinspecif
b
cell
product
infect
express
peptid
mhc
class
therefor
suscept
ctl
lysi
planz
et
al
parallel
kinet
neutral
antibodi
respons
human
noncytopath
poorli
cytopath
viral
infect
hbv
hcv
hiv
lcmv
strike
infect
neutral
antibodi
respons
becom
detect
month
viru
titer
reduc
low
undetect
level
viral
sensit
antibodi
neutral
viral
tropism
determin
structur
surfac
envelop
glycoprotein
modif
cell
tropism
may
alter
neutral
epitop
vice
versa
interact
best
illustr
murin
infect
lactat
dehydrogenaseelev
viru
ldv
arteriviru
caus
asymptomat
persist
infect
cytopath
replic
renew
subpopul
macrophag
v
plagemann
et
al
persist
favor
specif
polylactosaminoglycan
chain
ectodomain
primari
envelop
glycoprotein
mask
singl
antibodi
neutral
epitop
therefor
decreas
viral
immunogen
ldv
strain
lack
specif
chain
sensit
antibodi
neutral
abl
establish
lifelong
infect
howev
strain
also
shown
neuropathogen
miss
glycosyl
allow
viral
interact
put
receptor
anterior
horn
neuron
caus
paralyt
diseas
condit
impair
neutral
antibodi
respons
similar
interact
suspect
hiv
macrophag
cell
tropism
determin
envelop
glycoprotein
bind
coreceptor
nab
shown
abl
prevent
associ
trkola
et
al
chang
neutral
sensit
could
directli
affect
hiv
tropism
subsequ
studi
howev
demonstr
antibodymedi
neutral
hiv
independ
coreceptor
usag
trkola
et
al
montefiori
et
al
lacass
et
al
molecular
basi
viral
immun
select
lie
extens
genet
variat
virus
gener
mutat
recombin
reassort
genom
segment
rna
virus
particularli
high
spontan
mutat
rate
substitut
per
nucleotid
per
round
replic
consequ
absenc
proofreadingrepair
mechan
rna
polymeras
retrovir
revers
transcriptas
holland
et
al
virus
therefor
present
homogen
popul
host
circul
quasispeci
evolut
quasispeci
depend
popul
size
viru
competit
fit
variant
life
cycl
environment
factor
immun
respons
particular
cell
tissu
host
drug
act
continu
posit
select
pressur
viral
recognit
tropism
domingo
holland
within
quasispeci
viru
variant
contain
mutat
envelop
glycoprotein
could
alter
recognit
nab
would
posit
select
situat
humor
respons
play
substanti
role
viru
control
sever
mechan
may
account
immun
escap
neutralizationresist
mutant
first
amino
acid
substitut
within
neutral
determin
may
alter
affin
nab
virion
wiley
et
al
second
mutat
distant
site
may
chang
global
conform
antigen
determin
diamond
et
al
final
mutat
may
allow
addit
glycosyl
site
may
mask
neutral
epitop
skehel
et
al
wright
et
al
reitter
et
al
kimata
et
al
chen
et
al
v
antigen
variat
virus
orthomyxovirida
famili
compos
segment
rna
genom
long
paradigm
studi
escap
nab
respons
webster
et
al
wilson
cox
first
influenza
type
virus
may
show
genet
reassort
human
anim
strain
mainli
avian
swine
reservoir
thu
novel
pandem
strain
emerg
distinct
antigen
characterist
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
cox
subbarao
phenomenon
known
antigen
shift
second
accumul
singlepoint
mutat
within
ha
na
gene
influenza
b
virus
occur
natur
process
call
antigen
drift
respons
annual
recurr
influenza
epidem
amino
acid
chang
cluster
within
five
mainli
one
three
major
antigen
site
surfac
glycoprotein
wiley
et
al
sever
observ
indic
mutat
select
ongo
nab
respons
variant
similar
mutat
select
monoclon
antibodi
yewdel
et
al
furthermor
evid
variat
antibodi
repertoir
individu
mice
immun
influenza
staudt
gerhard
final
neutral
escap
mutant
readili
select
sera
immun
mice
lambkin
et
al
indic
restrict
antibodi
repertoir
anim
although
individu
rare
abl
induc
antibodi
respons
five
neutral
domain
whole
spectrum
antiha
respons
found
human
popul
wang
et
al
therefor
epidemiolog
signific
antigen
variant
may
aris
select
popul
level
accumul
sequenti
mutat
line
observ
shown
four
amino
acid
chang
occur
least
two
five
antigen
site
ha
need
variant
antigen
drift
epidemiolog
relev
wiley
et
al
although
antigen
variant
cytopath
rna
virus
rabi
viru
polioviru
footandmouth
diseas
viru
measl
viru
select
presenc
neutral
monoclon
antibodi
diamond
et
al
mateu
et
al
schrag
et
al
borrego
et
al
vivo
role
escap
humor
respons
viral
persist
natur
infect
unclear
hovi
et
al
may
import
gebauer
et
al
altern
explan
antigen
diversif
may
random
occurr
toler
amino
acid
replac
within
antigen
site
may
less
stringent
structur
requir
locat
surfac
envelop
glycoprotein
domingo
et
al
furthermor
amino
acid
substitut
may
occur
consequ
select
forc
chang
viruscel
receptor
interact
tropism
would
v
secondarili
affect
antigen
specif
et
al
kaplan
et
al
although
hepat
b
viru
hbv
doublestrand
dna
genom
life
cycl
includ
intracellular
rna
pregenom
intermedi
reversetranscrib
within
nucleocapsid
lee
step
respons
high
viral
mutat
rate
found
hbv
associ
cellular
immun
respons
nab
hbv
envelop
antigen
play
major
role
viral
clearanc
readili
detect
patient
clear
viru
patient
chronic
hbv
infect
chisari
ferrari
antigen
variat
surfac
glycoprotein
shown
clinic
import
sever
point
view
first
vaccineinduc
escap
mutant
hbv
describ
carman
et
al
show
incid
endem
region
second
passiv
immunoprophylaxi
polyclon
hbvspecif
ig
order
prevent
perinat
transplantationassoci
viral
transmiss
may
select
nabescap
variant
carman
et
al
hsu
et
al
protzerknol
et
al
third
natur
occur
mutat
gene
code
surfac
protein
associ
viral
persist
ogura
et
al
final
detect
hbv
patient
infect
viru
contain
mutat
within
surfac
antigen
hbsag
may
possibl
use
standard
hbsag
assay
carman
et
al
problem
great
public
health
signific
hepat
c
viru
hcv
positivesens
singlestrand
rna
viru
flavivirida
famili
rice
sever
line
evid
indic
nab
respons
exert
select
pressur
hypervari
region
envelop
glycoprotein
emerg
autolog
nabescap
variant
observ
chronic
hcv
infect
weiner
et
al
shimizu
et
al
experiment
hcv
infect
model
chimpanze
antiserum
induc
protect
homolog
hcv
infect
emerg
neutral
escap
mutant
alreadi
present
innoculum
farci
et
al
rate
sequenc
variat
region
chronic
hcv
infect
lower
absenc
humor
immun
respons
demonstr
patient
hypogammaglobulinemia
booth
et
al
furthermor
increas
viral
divers
associ
lack
control
hcv
infect
farci
et
al
human
immunodefici
viru
hiv
escap
humor
immun
recent
review
emerg
neutral
v
albert
et
al
tremblay
wainberg
arendrup
et
al
moog
et
al
bradney
et
al
howev
autolog
nab
respons
primari
isol
natur
infect
usual
weak
passiv
immun
hiv
ig
sever
broadli
neutral
monoclon
antibodi
experiment
chimer
infect
macaqu
provid
protect
mascola
et
al
mascola
et
al
shibata
et
al
baba
et
al
indic
certain
condit
hiv
nab
abl
provid
immunolog
select
pressur
poignard
et
al
strong
cytotox
cell
respons
respons
acut
viral
clearanc
lcmv
kagi
et
al
indirect
evid
bcelldefici
mice
well
passiv
immunoprophylaxi
studi
suggest
import
role
nab
longterm
viral
control
thomsen
et
al
baldridg
et
al
planz
et
al
lcmv
infect
ctldefici
mice
provid
opportun
demonstr
direct
clearanc
nab
ciurea
et
al
howev
viral
control
humor
respons
transient
reemerg
viru
variant
shown
neutralizationescap
mutant
display
one
three
singl
amino
acid
substitut
within
three
region
envelop
one
amino
acid
chang
previous
shown
occur
follow
immun
pressur
neutral
monoclon
antibodi
seiler
et
al
substitut
alter
neutral
polyclon
lcmvimmun
sera
select
monoclon
antibodi
ciurea
et
al
interestingli
new
nab
respons
emerg
viru
mutant
elicit
shown
consequ
timedepend
induct
cell
unrespons
therefor
lack
help
high
viremia
ciurea
et
al
interestingli
origin
wildtyp
strain
induc
respons
emerg
variant
mutant
virus
abl
induc
nab
inhibit
wildtyp
escap
variant
ciurea
et
al
ciurea
et
al
therefor
nab
respons
subsequ
emerg
lcmv
variant
seem
recapitul
evolut
new
sort
coevolutionarili
direct
archetyp
connect
phenomenon
somewhat
differ
shown
influenza
viru
infect
context
preexist
immun
memori
call
origin
antigen
sin
franci
et
al
fazeka
de
st
groth
webster
b
case
infect
escap
mutant
follow
antigen
drift
influenza
individu
gener
higher
hemagglutinationinhibit
antibodi
titer
origin
viru
drift
variant
v
host
viru
repres
two
side
evolutionari
equilibrium
cytopath
agent
usual
kill
immunolog
low
late
respond
wherea
high
earli
respond
tend
surviv
gener
presenc
neither
memori
b
cell
improv
condit
unless
antibodi
preexist
cell
activ
neither
effici
gener
standard
vaccin
strategi
review
ahm
swain
bradley
gray
zinkernagel
et
al
ahm
gray
zinkernagel
unprim
host
surviv
first
infect
host
need
immunolog
memori
surviv
second
infect
cours
host
die
due
primari
infect
immunolog
memori
obsolet
immunolog
memori
therefor
must
confer
evolutionari
advantag
speci
advantag
may
stem
fact
matern
immunolog
memori
provid
protect
immunoincompet
newborn
vertebr
zinkernagel
mhcrestrict
cell
recognit
requir
mhc
polymorph
immunoincompet
newborn
necessari
prevent
potenti
hostvsgraft
graftvshost
reaction
addit
immunodefici
offspr
lack
reactiv
ensur
immunosuppress
mother
absenc
mhcag
express
maternalfet
interfac
booy
et
al
sarva
et
al
studi
group
brent
siegrist
et
al
consequ
protect
offspr
critic
period
mediat
matern
memori
passiv
transfer
solubl
antibodi
impress
exampl
success
transfer
matern
memori
illustr
fact
calv
born
complet
without
serum
ig
must
take
colostr
matern
ig
within
first
hour
birth
review
brambel
occur
calv
remain
without
protect
antibodi
usual
die
variou
infect
next
week
mainten
matern
antibodi
memori
requir
provid
offspr
protect
infecti
agent
complet
primari
antibodi
repertoir
suffici
cover
relev
infecti
agent
gener
day
human
pregnanc
day
mous
pregnanc
therefor
b
cell
memori
need
order
accumul
immunolog
experi
pregnanc
addit
hormon
may
well
help
maintain
protect
antibodi
level
mother
increas
plasma
cell
surviv
might
explain
time
higher
incid
autoantibodymedi
autoimmun
diseas
femal
therefor
protect
newborn
main
key
evolutionari
basi
immunolog
memori
addit
qualiti
includ
herd
immun
individu
fit
could
contribut
coevolutionari
balanc
phenotyp
v
immun
respons
protect
cytopath
viru
infect
key
speci
surviv
without
except
protect
type
agent
mediat
protect
antibodi
noncytopath
virus
usual
transmit
time
birth
offspr
immunoincompet
appar
disadvantag
surviv
speci
exampl
includ
lcmv
row
hotchin
ciurea
et
al
mammari
tumor
viru
mmtv
achaorbea
palmer
leukemia
virus
mice
hepat
b
viru
human
michalak
et
al
rehermann
et
al
although
presenc
high
titer
nab
may
reduc
prevent
transmiss
infect
mother
offspr
overal
protect
immun
realli
necessari
surviv
speci
therefor
take
consider
account
becom
evid
order
understand
protect
immunolog
memori
cytopath
virus
studi
memori
respons
relev
discuss
previous
protect
evolutionarili
import
lytic
viru
infect
includ
frequent
contract
childhood
larg
mediat
nab
although
well
recogn
memori
antibodi
titer
tend
decreas
time
therefor
mechan
evolv
help
sustain
antibodi
level
matern
antibodi
shown
particip
deposit
immun
complex
follicular
dendrit
cell
offspr
help
maintain
antibodi
memori
nossal
et
al
tew
et
al
bachmann
et
al
altern
period
reinfect
either
extern
sourc
polioviru
herpesviru
influenza
parainfluenza
mani
intestin
virus
intern
foci
persist
infecti
agent
hbv
hiv
variou
herpesvirus
provid
natur
booster
immun
virus
persist
host
intact
viru
particl
crippl
form
billet
et
al
exampl
measl
viru
persist
subacut
scleros
panenceph
sspe
patient
also
appar
infect
host
katayama
et
al
explain
classic
epidemiolog
studi
faro
pacif
island
protect
memori
maintain
year
previous
infect
survivor
born
island
last
epidem
mim
two
studi
provid
evid
presenc
longliv
bone
marrow
plasma
cell
follow
immun
ovalbumin
infect
lcmv
manz
et
al
slifka
ahm
contrast
extens
analysi
b
cell
memori
longterm
antibodi
titer
post
vsv
lcmv
infect
v
indic
although
memori
b
cell
may
longliv
antibodi
secret
plasma
cell
shortliv
ochsenbein
et
al
studi
reveal
order
maintain
longterm
antibodi
titer
continu
antigendriven
tcelldepend
differenti
b
cell
plasma
cell
must
occur
differ
result
studi
explain
first
two
studi
slifka
ahm
analyz
b
cell
memori
bind
antibodi
use
elisa
assay
ochsenbein
et
al
studi
protect
neutral
antibodi
respons
replic
nonrepl
antigen
addit
bind
antibodi
outlin
protect
primari
infect
andor
reinfect
acut
cytopath
virus
larg
depend
nab
christian
et
al
bachmann
zinkernagel
bachmann
et
al
neutral
antibodi
also
influenc
infect
noncytopath
lcmv
baldridg
buchmeier
thomsen
et
al
planz
et
al
irrelev
ovalbumin
contrast
role
nonneutr
antibodi
host
protect
neglig
lcmv
vsv
infect
discrep
studi
may
reflect
differ
avid
antibodi
probabl
lower
elisa
higher
neutral
bachmann
et
al
andor
perhap
import
differ
number
antigen
site
assess
one
neutral
mani
elisa
antigen
encount
specif
b
lymphocyt
undergo
clonal
expans
expand
pool
antigenspecif
b
cell
produc
faster
stronger
respons
upon
antigen
reencount
recent
studi
maruyama
et
al
gener
mice
induc
genet
switch
bcr
gener
memori
b
cell
complet
absenc
specif
antigen
clearli
demonstr
memori
b
cell
persist
long
period
time
absenc
antigen
stimul
howev
outlin
evolutionari
point
view
memori
b
cell
suffici
protect
memori
addit
differenti
antibodysecret
plasma
cell
earli
enough
follow
reinfect
cytopath
viru
mount
protect
antibodi
titer
thu
maintain
longterm
protect
antibodi
titer
longliv
antigenindepend
memori
b
cell
remind
antigen
differenti
shortliv
antibodysecret
plasma
cell
discuss
ochsenbein
et
al
cell
memori
focu
review
interest
note
import
differ
b
cell
memori
cytotox
cell
key
function
control
noncytopath
virus
acut
infect
although
protect
period
may
also
harm
host
caus
immunopatholog
destruct
infect
cell
therefor
must
control
review
zinkernagel
et
al
exampl
lethal
v
textur
neutral
antivir
antibodi
respons
graftvshostlik
immunopatholog
induc
inject
high
dose
viral
peptid
prime
mous
high
precursor
frequenc
virusspecif
ctl
immunopatholog
probabl
occur
result
peptid
load
mani
host
cell
includ
cell
immun
system
kill
prime
ctl
aichel
et
al
therefor
memori
nab
respons
requir
protect
cytopath
infect
ctl
protect
noncytopath
acut
infect
increas
precursor
frequenc
may
actual
harm
contrast
matern
antibodi
ctl
respons
transmit
offspr
transplant
antigen
differ
mother
offspr
potenti
caus
graftvshost
reaction
addit
specif
matern
cell
recogn
patern
mhcpeptid
configur
offspr
would
therefor
useless
therefor
prime
ctl
may
function
primarili
prevent
viru
spread
within
host
limit
prevent
immunopatholog
diseas
kundig
et
al
bachmann
et
al
exampl
illustr
point
spectrum
virushost
relationship
found
hbv
hiv
infect
human
viru
control
low
level
chronic
diseas
either
develop
develop
late
howev
viru
control
sever
autoaggress
diseas
aggress
form
hbvhepat
may
develop
similar
balanc
exist
lepra
tuberculosi
infect
exampl
lowlevel
infect
maintain
protect
immun
review
bianchi
mondelli
eddleston
chisari
ferrari
macka
introduc
term
infecti
immun
infect
immun
describ
import
coevolutionari
equilibrium
macka
macka
conclud
although
immunolog
memori
consid
indispens
compon
individu
immun
system
may
idea
fact
protect
immunolog
memori
like
reflect
lowlevel
respons
driven
maintain
persist
reencount
antigen
antigendriven
memori
respons
would
protect
host
direct
damag
infect
indirect
immunopatholog
mediat
damag
mediat
infecti
agentspecif
cell
antibodi
importantli
evolutionari
point
view
antibodi
memori
protect
offspr
physiolog
phase
immunodefici
consid
success
vaccin
compar
infecti
diseas
effici
protect
vaccin
lack
review
nossal
strike
note
success
vaccin
induc
high
level
nab
necessari
suffici
protect
host
diseas
success
vaccin
infecti
diseas
tuberculosi
leprosi
v
hiv
would
requir
induct
addit
longlast
cell
respons
control
infect
although
longlast
nab
respons
effici
gener
classic
vaccin
strategi
yet
abl
gener
vaccin
mimic
infect
persist
low
level
provid
necessari
longterm
cell
immun
gener
neutral
antibodi
central
success
vaccin
develop
polioviru
vaccin
serv
good
exampl
nathanson
martin
sabin
neutral
antibodi
form
mucos
iga
serum
igg
prevent
reduc
infect
earli
stage
sabin
inactiv
salk
vaccin
induc
longlast
igg
respons
serum
prevent
circul
viru
reach
central
nervou
system
sinc
none
success
vaccin
abl
complet
prevent
reinfect
gener
accept
mode
action
greatli
reduc
system
spread
infecti
agent
induct
nab
analysi
success
vaccin
strategi
may
perhap
reveal
certain
vaccin
includ
mump
arya
strohl
et
al
measl
ofosuamaah
garenn
et
al
malfait
et
al
wild
bennett
et
al
paramyxovirus
less
effect
therefor
subject
critic
oppon
vaccin
mump
vaccin
alway
prevent
reinfect
salivari
gland
germann
et
al
strohl
et
al
howev
sever
form
diseas
orchiti
enceph
occur
vaccin
children
find
may
indic
follow
system
vaccin
lowdos
vaccin
local
mucos
immun
may
suffici
high
enough
protect
reinfect
howev
similar
sabin
vaccin
even
though
local
breakthrough
occur
mucosa
system
diseas
develop
viru
trap
neutral
igg
blood
similar
consider
may
appli
measl
vaccin
although
consequ
reinfect
sever
system
measl
immun
may
provid
suffici
titer
local
antibodi
prevent
infect
throat
tonsil
addit
measl
viru
capac
caus
immunosuppress
interf
apc
b
cell
function
review
mcchesney
oldston
interestingli
may
also
appli
attenu
vaccin
strain
increas
incid
insuffici
vaccin
protect
togeth
possibl
matern
antibodi
may
interfer
effici
vaccin
earli
childhood
sabin
et
al
englund
et
al
siegrist
et
al
great
concern
particularli
thirdworld
countri
gwatkin
attempt
enhanc
measl
vaccin
efficaci
innoculum
dose
increas
v
textur
neutral
antivir
antibodi
respons
factor
led
late
diseas
develop
children
therefor
stop
gwatkin
exampl
show
even
attenu
virus
given
high
dose
caus
diseas
compar
lowdos
infect
wildtyp
virus
detail
complic
measl
still
unknown
requir
evalu
nevertheless
exampl
demonstr
attenu
viru
go
yield
optim
vaccin
instanc
wildtyp
measl
also
interest
may
persist
host
long
time
possibl
death
katayama
et
al
whether
also
appli
vaccin
strain
yet
known
howev
import
determin
measl
viru
persist
long
addit
whether
persist
viru
necessari
suffici
maintain
longterm
protect
whether
vaccin
strain
also
caus
sspe
must
investig
c
attenu
vaccin
provid
insuffici
protect
caus
diseas
whether
attenu
virus
alway
good
vaccin
candid
debat
question
recent
discuss
use
natur
occur
nefdefici
hiv
human
attenu
siv
strain
monkey
exampl
ruprecht
although
attenu
strain
initi
caus
immunodefici
eventu
human
monkey
develop
diseas
die
similarli
hiv
infect
success
longterm
protect
vaccin
tuberculosi
leprosi
still
avail
bloom
ahm
bloom
mckinney
contrast
wildtyp
tuberculosi
bacillu
calmetteguerin
bcg
appar
persist
human
year
correl
time
protect
tuberculosi
young
children
suggest
persist
infect
requir
mainten
activ
cell
respons
limit
granuloma
size
order
avoid
immunopatholog
yet
sustain
longlast
immun
respons
bloom
mckinney
summari
attenu
vaccin
strain
yet
imit
optim
mixtur
infect
immun
defin
macka
macka
macka
similarli
ctl
respons
necessari
control
infect
hiv
hcv
herpesvirus
attenu
virus
success
time
dna
vaccin
may
promis
candid
provid
lowdos
persist
antigen
sourc
guarante
longterm
activ
b
cell
discuss
vaccin
strategi
also
includ
old
hope
mimick
neutral
epitop
use
linear
peptid
would
provid
safe
nonrepl
vaccin
induc
longlast
titer
nab
theoret
v
strategi
success
shown
effect
rare
exampl
footandmouth
diseas
viru
bittl
et
al
addit
use
linear
peptid
loop
hiv
provid
limit
success
vitro
yet
yield
success
vivo
conley
et
al
gener
difficult
imit
serotypespecif
threedimension
structur
neutral
epitop
particularli
true
high
avidityneutr
antibodyantigen
interact
reason
probabl
rest
simpl
fact
neutral
epitop
gener
linear
compos
two
loop
protein
chain
studi
neutral
antibodi
virus
bacteria
toxin
larg
neglect
past
year
howev
numer
studi
focus
induct
bind
antibodi
solubl
protein
antigen
ovalbumin
hapten
although
classic
studi
provid
insight
b
cell
antibodi
function
reevalu
conclus
reach
time
necessari
one
major
reason
neglect
studi
antivir
antibodi
respons
perhap
tcellmedi
immun
occupi
much
interest
immunologist
recent
mani
new
tool
develop
allow
analysi
b
cell
neutral
antibodi
respons
level
imagin
year
ago
antibodi
sequenc
rapidli
transgen
geneknockout
mice
permit
evalu
precis
immunolog
function
advanc
molecular
virolog
provid
mani
new
fascin
research
perspect
neutral
antibodi
evolutionarili
import
effector
immun
virus
evalu
reveal
number
basic
insight
specif
rule
reactiv
toler
memori
specif
neutral
antibodi
defin
capac
distinguish
viru
serotyp
b
cell
reactiv
determin
antigen
structur
concentr
time
avail
secondari
lymphoid
organ
b
cell
memori
provid
elev
protect
antibodi
titer
serum
depend
antigen
stimul
perhap
slightli
overst
rule
simpl
correl
vivo
evid
well
clinic
observ
appear
larg
demystifi
mani
specul
antibodi
b
cell
physiolog
implic
vaccin
obviou
therefor
care
critic
assess
review
experiment
evid
concept
great
import
v
